Treatment results and predictors of local recurrences after breast conserving therapy in early breast carcinoma
|
|
- Alexia Horton
- 5 years ago
- Views:
Transcription
1 Journal of BUON 8: , Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Treatment results and predictors of local recurrences after breast conserving therapy in early breast carcinoma V. Parvanova, V. Pandova Department of Radiotherapy, National Hospital of Oncology, Sofia, Bulgaria Summary Purpose: The aim of this study was to access the influence of several factors on local control (LC) and overall survival (OS) in patients with early breast cancer after breast-conserving therapy. Patients and methods: 122 early breast cancer patients with tumor (T) up to 3 cm and breast-conserving surgery followed by radiotherapy, chemotherapy, or hormonal therapy were retrospectively analysed. Factors considered to carry possible significance in relation with local recurrence were classified into 3 groups that included characteristics of the patient, of the tumor and the non-surgical treatment methods applied. Results: With a median follow-up of 63.5 months (range months) LC was achieved in 116 (95.1%) patients. The median time to local recurrence was 30.3 months (range months). Of all the factors examined in the 3 groups, a negative statistical impact on LC was found only in high-risk node-negative patients (tumor size over 2 cm, high grade of malignancy, and absence of steroid receptors (SR); p=0.02). Ten-year OS was 95.8%, with statistical significance favoring stage I patients (98.5% versus 87.5% for stage I and II, respectively; p=0.05). Ten-year recurrencefree survival was 89.4%. Postponement of radiotherapy after chemotherapy did not change significantly either LC or OS (p >0.46). Adjuvant chemotherapy was administered to 22 (83.3%) node-positive patients, but only to 1 (12.5%) of node-negative high-risk patients. This resulted in unsatisfactory OS for the latter group of patients (90.2% versus 73.4%; p <0.000). Conclusion: In high-risk node-negative early breast cancer patients, the occurrence of early local recurrences and distant metastasis defines an aggressive disease behavior. Chemotherapy administration and its timing in relation with the delivery of radiotherapy constitutes an issue of future research for this group of patients. Key words: breast-conserving therapy, chemotherapy, local recurrence, predictive factors, radiotherapy without boost, skin recurrence Introduction Some of the key decisions in the current management of primary breast cancer involve the need Received ; Accepted Author and address for correspondence: Dr Vesselina Parvanova National Hospital of Oncology 6 Plovdivsko Pole Street 1756 Sofia Bulgaria Tel: , ext 323 Fax: v_parvanova@yahoo.co.uk for prognostication. The most relevant factors for the estimation of the risk for recurrence remain the nodal status and the number of the involved lymph nodes [1,2]. For patients with node-negative presentation, pathologic tumor size (T), histologic and nuclear grade (G), the absence or presence of SR in the tumor and age are factors considered to define differential prognosis [3-6]. Breast irradiation is clearly indicated after breastconserving surgery, and addition of radiotherapy to surgery has resulted in a 3-fold lower local recurrence rate compared with surgery alone [7,8]. Radiotherapy, as part of such treatment programs, should be delivered with modern techniques designed to reduce the volume of heart and great vessels receiving radiation, and must be coordinated with adjuvant che-
2 242 motherapy and/or hormonal therapy [9]. In most of the studies, high risk for local recurrences after breast -conserving therapy is related to the presence of positive surgical margins, and in some of them with younger patients age (less than 40 years) [6,10,11]. High risk for distant metastasis is associated with early occurrence of local recurrences involving the skin without involvement of the parenchyma of the remaining breast, or with supraclavicular nodal metastasis [12-14]. In this paper we tried to evaluate the effectiveness of radiotherapy and chemotherapy or hormonotherapy in patients with breast-conserving surgery of early breast carcinoma (stages I II) by evaluating factors affecting LC and OS. Patients and methods Between breast cancer patients with T up to 3 cm, N0-1, M0 completed their postoperative therapy at the Department of Radiotherapy, National Hospital of Oncology, Sofia. Breast-preserving operation was followed by radiotherapy, adjuvant chemotherapy, and antiestrogen therapy. Factors considered to carry prognostic significance for local recurrence were classified into 3 groups: 1. Characteristics of the patient: age, menstrual status, breast size, accompanying diseases damaging the small vessels, such as diabetes mellitus and arterial hypertension and related to high risk of irradiation damages, mastopathy, breast cancer family history in 1st and 2nd degree relatives, thyroid dysfunction and tumor localization in the breast. 2. Characteristics of the tumor: tumor size, axillary nodal status (number and level of involved lymph nodes), histological type, grade of malignancy, SR status, presence of extensive intraductal component (EIC), and stage of disease. T, G, and SR status in node-negative patients defined 3 risk groups of patients for distant metastasis, OS and the need for systemic adjuvant therapy (Table 1) [15]. 3. Characteristics of the applied treatment methods: total radiation dose, dose in organs at risk, clinical target volumes (CTV), ± adjuvant chemotherapy, ± adjuvant hormonotherapy, timing of application of radiotherapy and chemotherapy or hormonotherapy. Treatment methods Surgery Surgical treatment comprised quadrantectomy or lumpectomy with histologically confirmed negative resection margins, and radical axillary node dissection (all 3 levels) with more than 10 histologically confirmed resected lymph nodes. Systemic treatment Postoperative adjuvant chemotherapy was administered to 31 (25%) of all patients ( % patients with positive axillary lymph nodes, and 9-9.5%) patients with negative axillary lymph nodes), its application depending on disease stage (Figure 1). Three courses of CMF (cyclophosphamide, methotrexate and 5- fluorouracil) or CEF (cyclophosphamide, epirubicin and 5-fluorouracil) were administered before radiotherapy, and another 3 courses after the completion of radiotherapy. Adjuvant tamoxifen was given to patients with positive SR. In the first years of the study, tamoxifen was also given to some SR-negative or SR-unknown patients. Radiotherapy Radiotherapy was delivered to all of the patients. CTV included the preserved breast and the underlying chest wall (CTV I), and CTV II the supraclavic- Table 1. Risk groups and the need for systemic adjuvant treatment in node-negative patients[15] Tumor factors Low risk Moderate risk High risk T* (cm) <1 1-2 >2 SR Positive Positive Negative G G1 G1-2 G2-3 Systemic No treatment Adjuvant anti- Adjuvant treatment needed in the estrogen therapy chemotherapy presence of all 3 factors *tumor size; steroid receptors; grade of malignancy Figure 1. Patients with chemotherapy according to disease stage.
3 243 ular lymph nodes in patients with more than 3 positive axillary lymph nodes [16]. The prescribed dose in planning target volume (PTV) I was 50 Gy in 25 fractions, 5 times per week with no boost to the tumor bed, and in PTV II 44 Gy in 22 fractions, 5 times per week. Tolerant doses to organs at risk were: lungs 30Gy up to a depth of 3 cm calculated in the central lung distance of the central axis; front wall of the myocardium of the left ventricle 30Gy; and contralateral breast 5Gy. Statistical methods In the statistical analysis parametric methods were used, and proportions and means were compared by the x 2 test of Pearson and Fisher, respectively. Life table analyses were done using the Kaplan-Meier method. All tests were carried out using the SPSS software package. Survival was measured from the date of breast cancer diagnosis. The sufficient number of the studied cases and the adequate length of the follow-up period gave good reliability to the results and conclusions of this study. Results The median patients follow-up period was 63.5 months (range months). Most of the patients were premenopausal with Table 2. Patient characteristics (n=122) Characteristic n (%) Age (years, median 50) (18.9) (45.9) (11.5) >61 29 (23.7) Premenopausal 59 (51.6) Perimenopausal 26 (21.3) Postmenopausal 37 (30.3) Mastopathy 58 (47.5) Thyroid dysfunction 20 (16.4) Family history 20 (16.4) Breast size small 18 (14.8) medium 85 (69.7) large 19 (15.5) Tumor localization upper-lateral 88 (72.0) outer-lateral 22 (18.0) outer-medial 4 (3.0) upper-medial 8 (7.0) Table 3. Tumor characteristics (n=122) Characteristic n (%) Tumor size (cm) T1a < (11.5) T1b (44.3) T1c (38.5) T (5.7) Nodal status N 95 (77.9) N + 27 (22.1) Metastatic axillary lymph nodes (n) 1 21 (17.2) 2 4 (3.3) 3 2 (1.6) Stage I 90 (73.8) IIA 30 (24.6) IIB 2 (1.6) EIC 15 (12.2) Tumor grade G1 50 (41.0) G2 37 (30.3) G3 29 (23.8) unknown 6 (4.9) Steroid receptor status SR+ 85 (69.7) SR- 17 (13.9) unknown 20 (16.4) Risk group* low 41 (33.6) moderate 46 (37.7) high 8 (6.6) * in node-negative patients For abbreviations see text tumors in the upper-lateral quadrant (Table 2). Half of the patients with thyroid dysfunction had stage II disease in contrast with only 21% of those without such a dysfunction (p < 0.01). Most of the patients (55.8%) had tumors up to 1 cm, with negative axilla (77.9%; Table 3). No correlation was found between histological tumor type and age of the patients; however, mucinous carcinomas showed a trend to appear in older patients. Mucinous, papillary, medullary and tubular histologies showed a statistically significant prevalence of low grade malignancy (p=0.03). In our study all of the patients had a negative resection line, and 15 (12.2%) of them an EIC accompanying the invasive tumor. The CTV I was applied in 107 (87.7%) patients, while the additional CTV II was applied in another 15 (12.3%) patients. The latter group represented 46.8% of stage II patients, while the rest of stage II nodepositive patients received chemotherapy without supraclavicular lymph node irradiation.
4 244 An average dose of Gy was applied for CTV I, without boost to the tumor bed. Patients with CTV II received Gy at a depth of 3 cm. In 92 (75.5%) of all patients (91 without chemotherapy and 1 with chemotherapy) radiotherapy started days postoperatively. Thirty (24.5%) patients started radiotherapy approximately 3 months postoperatively, after 3 courses of adjuvant chemotherapy. Chemotherapy in node-negative patients was administered as follows: in the group with low risk for distant metastasis no chemotherapy was given; in the group with moderate risk chemotherapy was given to 8 (17.4%) of the cases; and in patients with high risk it was given only to 1 (12.5%) of them after the end of radiotherapy. Chemotherapy was administered to 22 (83.3%) node-positive patients. Hormonal therapy with tamoxifen was administered to 83 (68%) of all the patients. It was given to 70 (82.4%) patients with positive SR, to 3 (17.6%) with negative SR and to 10 (50%) with unknown SR. Ten-year LC was achieved in 116 (95.1%) of the patients, while 6 (4.91%) patients developed locoregional recurrence (Table 4). The median time to locoregional relapse was 30.3 months (range months). There was no statistically significant correlation between local recurrences and tumor size and disease stage. Three of the local recurrences were skin lesions of the preserved breast without involvement of the breast parenchyma, had the same histology with the primary tumor and measured up to 1.5 cm. One patient developed breast cancer in the remaining breast, with a different histology from the primary tumor. Two patients developed metastatic supraclavicular lymph nodes, without recurrence in the breast. Two patients with skin localization and one with supraclavicular nodal metastasis developed distant metastasis in the lung and liver after 1 and 2.9 months, respectively. Another patient developed cancer in the other breast after 20 months. The tumor had the same histology with the first one. Seven (5.7%) patients developed distant metastasis (2 liver, 3 bone, 1 brain and 1 lung disease), Table 4. Ten-year locoregional recurrence Locoregional recurrence n (%) Remaining breast / skin 1/3 (3.27) Supraclavicular nodes 2 (1.64) Total 6 (4.91) Figure 2. Ten-year recurrence-free survival. after a median of 24.8 months (range months). Only 2 of them had also locoregional relapse. The achieved very good therapeutic results with conservative treatment of early breast carcinoma (Figure 2) did not allow the distinction of risk factors for LC and OS with high statistical value. Factors related to patient characteristics The age of patients, distributed in 4 groups (Table 2), did not show statistical connection with the occurrence of local relapses (p=0.5), distant metastasis (p=0.2) or OS (p=0.3). Also, the menopausal status, presence of mastopathy, and size of the breast did not show any significant relation with LC, distant metastasis or OS. Fifty percent of patients with thyroid dysfunction had stage II disease versus 21% of the patients without thyroid dysfunction (p=0.02). Thirty-seven percent of the patients with thyroid dysfunction developed distant metastasis with statistically significant difference in mortality between patients with or without thyroid dysfunction (10% versus 1.9%, p=0.01), which is a reason for future studies. Patients with family history for breast cancer did not show worse results in terms of LC, distant metastasis or OS compared to those without such a history. The localization of the primary tumor in topographic quadrants of the breast was not connected with LC or distant metastasis (p=0.9). Factors related to tumor characteristics All of the patients in the present study had histologically confirmed negative surgical margins. Cases with EIC accompanying invasive tumor did not show a difference in the occurrence of local recurrences or OS. Tumor size up to 2 cm, the presence of positive axillary lymph nodes and their number, the presence of negative SR and a high grade of malignancy did not differ as single unfavorable risk factors concerning LC as well as OS. The stage of disease did not show any significant relation with LC, but a significant relation with OS was noted (98.5% versus 87.5% for stage I and II, respectively; p=0.05).
5 245 both LC and OS were significantly related with chemotherapy administration in high-risk node-negative patients. Discussion Figure 3. Local recurrence (LR) and overall survival (OS) in different risk node-negative patients and in node-positive patients. Only when the combination of the unfavorable factors in node-negative patients (high grade of malignancy, tumor size >2 cm and absence of SR, forming the high risk group for OS) was taken into account, a statistically significant relation was found for the reduction not only of the OS but also of the LC rate (Figure 3). Factors related to treatment methods The applied doses and the different CTVs did not show any significant influence on treatment results. The administration of chemotherapy in all of the patients who received it did not show a statistically significant improvement of the LC rate, since 3.2% of the patients with postoperative chemotherapy recurred, compared to 4.3% of those without chemotherapy (p=0.30). Only 1 (12.5%) of the high-risk node-negative patients received chemotherapy, which resulted in high mortality (25%), compared to node-positive patients, where mortality was 7.4% (p=0.002; Figure 4). Thus Figure 4. Mortality in different risk node-negative patients and in node-positive patients. The occurrence of local relapses after breastconserving therapy is evaluated at 0.8% annually, which is characteristic for breast-conserving therapy of the early breast cancer. Most often, local failures after breast-conserving treatment are related with the status of the surgical margins and the age of the patient [9,10,17]. The influence of positive margins on the local tumor control is most powerful compared to the other factors (negative SR, G3, EIC), where the results are still controversial [1-4,18-20]. The treatment of node-negative patients varies substantially. In our study, only 1 (12.5%) of high-risk node-negative patients received chemotherapy after the end of radiotherapy because of risk underestimation. In this group of patients the 5-year OS was only 73%, which is even lower than the one observed in node-positive patients (90.2%). The 2 patients with skin recurrence and almost simultaneous development of distant metastasis makes us believe that these cases are not a failure of local treatment, but they may be considered as representing a process of aggressive disease dissemination, requiring the administration of adjuvant chemotherapy [21-24]. The highly selected group of patients in our study with negative surgical margins, tumor size up to 3 cm (only 5.7% of them had a tumor between 2 to 3 cm), and presence of more than 4 positive lymph nodes in 5% of the patients, does not enable a clear distinction of unfavorable factors for the development of local recurrences. Our results are in agreement with relevant studies, showing that early local recurrences and skin relapses are related to an aggressive disease followed by the development of distant metastasis [14,15,19,25]. Published data relate local relapses with reduced OS in node-negative patients with breastpreserving therapy of early breast cancer [21-23,25]; in our study the OS of high-risk node-negative patients reached 73.3% compared to 90.2% of nodepositive patients (Figure 3). The administration of chemotherapy, the combination of the drugs, the number of cycles and the sequence of its administration with radiotherapy or their concurrent application constitute an issue for future research in node-negative high-risk early breast cancer patients with breast-conserving therapy.
6 246 References 1. Goldhirsch A, Glick J, Gelber R, Coates R, Senn H. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 18: Kini VR, Vicini FA, Frazier R, Victor SJ, Wimbish K, Martinez AA. Mammographic, pathologic, and treatment-related factors associated with local recurrence in patients with early-stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys 1999; 43: Nixon A, Schnitt S, Gelman R et al. Relationship of tumor grade to other pathologic features and treatment outcome of patients with early stages of breast carcinoma treated with breast-conserving therapy. Cancer 1996; 78: Harrold EV, Turner BC, Matloff ET et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am 1998; 4: Fowble BL, Schultz DJ, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994; 30: Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: McBain CA, Young EA, Swindell R, Magee B, Stewart AL. Local recurrence of breast cancer following surgery and radiotherapy: incidence and outcome. Clin Oncol (R Coll Radiol) 2003; 15: van Dongen JA, Bartelink H, Fentiman IS et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur J Cancer 1992; 28A: Overgaard M. Radiotherapy as a part of multidisciplinary treatment strategy in early breast cancer. The European Cancer Conference Education Book, ECCO 11 Lisbon, October Eur J Cancer 2001 (Suppl 7): Fisher ER. Lumpectomy margins and much more. Cancer 1997; 79: Gage J, Schnitt S, Nixon A et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 1996; 78: Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002; 8: Gage I, Schnitt SJ, Recht A et al. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 1998; 16: Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Longterm results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys 2001; 51: Possinger K. Prognostic factors and tumor markers in breast cancer. Present and future. 8th Intern Congr Anticancer Treat, Paris, Feb 1998, EL-20, 40 (abstr). 16. Parvanova V, Pandova V. Radiotherapy without boost to the tumor bed after conservative surgery in the treatment of early breast cancer J BUON 1999; 4: Meric F, Mirza NQ, Vlastos G et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 2003; 97: Park CC, Mitsumori M, Nixon A et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000; 18: Voogd AC, van Tienhoven G, Peterse HL et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Cancer 1999; 85: Mirza NQ, Vlastos G, Meric F et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol 2002; 9: Vujovic O, Perera F, Dar AR et al. Does delay in breast irradiation following conservative breast surgery in nodenegative breast cancer patients have an impact on risk of recurrence? Int J Radiat Oncol Biol Phys 1998; 40: Rouzier R, Extra JM, Carton M et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 2001; 19: Leonard CE, Wood ME, Zhen B et al. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol 1995; 13: Polgar C, Fodor J, Orosz Z et al. The effect of tumour bed boost on local control after breast conserving surgery. First results of the randomized boost trial of the National Institute of Oncology. Magy Onkol 2001; 45: (in hungarian with engl abstr). 25. Le MG, Arriagada R, Spielmann M, Guinebretiere JM, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002; 94:
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationOUTCOME AND PROGNOSTIC FACTORS IN THE CONSERVATIVE TREATMENT OF BREAST CANCER
SPECIAL ISSUES IN BREAST CANCER OUTCOME AND PROGNOSTIC FACTORS IN THE CONSERVATIVE TREATMENT OF BREAST CANCER http://www.lebanesemedicaljournal.org/articles/57-2/doc12.pdf Elie NASR, Dolly NASR, Fares
More informationCHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD ( ) - A RETROSPECTIVE ANALYSIS
Archive of Oncology 2000;8(Suppl 1):7. SESSION 1 CHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD (1995-2000) - A RETROSPECTIVE ANALYSIS 7 Archive of Oncology 2000;8(Suppl 1):8. 8 Extended
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationReal-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study
Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationPostmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients
Original article UDC: 618.19-006:618.19-089.87:615.849.1 Arch Oncol 2004;12(1):39-43. Postmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients Danijela ÆEPANOVIÆ
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationOncologic safety of breast-conserving surgery in breast cancer patients under the age of 35
Korean Journal of Clinical Oncology 217;13:32-38 https://doi.org/1.14216/kjco.174 pissn 1738-882 eissn 2288-484 Original Article Oncologic safety of breast-conserving surgery in breast cancer patients
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationBreast-conserving therapy (BCT), in which surgery is restricted to
688 Effect of Breast-Conserving Therapy versus Radical on Prognosis for Young Women with Breast Carcinoma Niels Kroman, M.D. 1 3 Helle Holtveg, M.D. 4 Jan Wohlfahrt, M.Sc. 1 Maj-Britt Jensen, M.Sc. 2 Henning
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationClassifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology
2059 Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences Eugene Huang,
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 22 by the Massachusetts Medical Society VOLUME 347 O CTOBER 17, 22 NUMBER 16 TWENTY-YEAR FOLLOW-UP OF A RANDOMIZED STUDY COMPARING BREAST-CONSERVING SURGERY
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationPrediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography
Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman
More informationDifferences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: http://www.tandfonline.com/loi/ionc20 Differences in outcome for positive margins in a large cohort of breast cancer patients
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationAccuracy of Specimen Radiography in Assessing Complete Local Excision with Breast-Conservation Surgery
RESEARCH ARTICLE Editorial Process: Submission:09/22/2017 Acceptance:01/21/2018 Accuracy of Specimen Radiography in Assessing Complete Local Excision with Breast-Conservation Surgery Saira Naz, Imrana
More informationCONSERVATIVE therapy in the management of
Vol. 332 No. 14 BREAST CONSERVATION VERSUS MASTECTOMY IN STAGE I AND II BREAST CANCER 7 TEN-YEAR RESULTS OF A COMPARISON OF CONSERVATION WITH MASTECTOMY IN THE TREATMENT OF STAGE I AND II BREAST CANCER
More informationPost-mastectomy radiotherapy: recommended standards
Post-mastectomy radiotherapy: recommended standards H. Bartelink Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands Introduction The local recurrence rate after mastectomy
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationFamilial breast cancer. Part II: Relationships with histology, staging, steroid receptors and serum tumor markers
Journal of BUON 7: 61-65, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Familial breast cancer. Part II: Relationships with histology, staging, steroid receptors and serum
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationManagement of Early Breast Cancer with Breast Conservative Surgery. An Egyptian Experience
Journal of the Egyptian Nat. Cancer Inst., Vol. 1, No. 4, December: 71-78, 009 Management of Early Breast Cancer with Breast Conservative Surgery. An Egyptian Experience HAMDY EL-MARAKBY, M.D., FRCS. The
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationEffects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with
More informationAnalysis of loco-regional and distant recurrences in breast cancer after conservative surgery
Elsayed et al. World Journal of Surgical Oncology (2016) 14:144 DOI 10.1186/s12957-016-0881-x RESEARCH Analysis of loco-regional and distant recurrences in breast cancer after conservative surgery Mostafa
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationRecurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
More informationRadiotherapy and Oncology
Radiotherapy and Oncology 9 (29) 74 79 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Postmastectomy irradiation High local recurrence risk
More informationThe sequencing of chemotherapy and radiotherapy in breast cancer patients after mastectomy
Tumori, 96: 28-33, 2010 The sequencing of chemotherapy and radiotherapy in breast cancer patients after mastectomy Hak Jae Kim 1, Jae-Sung Kim 1, Eui Kyu Chie 1, Dong-young Noh 2, Yung-jue Bang 3, Sung
More informationCHAPTER 7 G.H.D E BO CK,J.A.VAN D ER HAGE,H.PU TTER,J.BO N N EM A,H.BARTELIN K,C.J.H.VAN D E VELD E
06 Prfschrft JvdH Binnenwerk 23-04-2006 16:07 Pagina 97 CHAPTER 7 Isolated loco-regional recurrence of breast cancer is m ore com m on in young patients and follow ing breast conserving th erapy: Long-term
More informationComparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients
http://dx.doi.org/10.7180/kmj.2016.31.1.19 KMJ Original Article Comparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients Yoon Seok
More informationGUIDELINES FOR RADIOTHERAPY IN EARLY BREAST CANCER
GUIDELINES FOR RADIOTHERAPY IN EARLY BREAST CANCER Authors: Dr N Thorp/ Dr P Robson On behalf of the Breast CNG Written: Originally - December 2008 Reviewed: Updated - December 2011 Agreed: Breast TSG
More informationRetrospective evaluation of operated stage I breast cancer patients
40 Turkish Journal of Cancer Volume 33, No.1, 2003 Retrospective evaluation of operated stage I breast cancer patients ABSTRACT As there is no national screening programme in our country, information about
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBreast Cancer in Young Adolescent: University of Port Harcourt Teaching Hospital 10 Year Experience.
Journal of Medical Science and Clinical Research Volume 1 Issue 4 Pages160-164 2013 Website: www.jmscr.igmpublication.org ISSN (e): 2347-176X2 Breast Cancer in Young Adolescent: University of Port Harcourt
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje
University of Groningen Local treatment in young breast cancer patients Joppe, Enje IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationBenefit of Internal Mammary Lymph Nodes Irradiation in Patients with Breast Cancer
Benefit of Internal Mammary Lymph Nodes Irradiation in Patients with Breast Cancer Amr El-Kashif, MD, Mohamed Abdelrahman, MD, Salah El-Mesidy, MD Department of Clinical Oncology, Faculty of Medicine,
More informationRADIOTHERAPY FOR STAGE II AND STAGE III BREAST CANCER PATIENTS WITH NEGATIVE LYMPH NODES AFTER PREOPERATIVE CHEMOTHERAPY AND MASTECTOMY
doi:10.1016/j.ijrobp.2010.12.054 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. e1 e7, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front matter
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationCitation Hong Kong Practitioner, 1996, v. 18 n. 2, p
Title Conservative surgery for breast cancer Author(s) Poon, RTP; Chow, LWC; Au, GKH Citation Hong Kong Practitioner, 1996, v. 18 n. 2, p. 68-72 Issued Date 1996 URL http://hdl.handle.net/722/45367 Rights
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 99, by the Massachusetts Medical Society Volume 332 APRIL 6, 99 Number ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE- POSITIVE BREAST CANCER The Results of Years of Follow-up
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationNo clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study
Annals of Oncology original articles Annals of Oncology 26: 1149 1154, 2015 doi:10.1093/annonc/mdv159 Published online 3 April 2015 No clear effect of postoperative radiotherapy on survival of breast cancer
More informationequally be selected on the basis of RE status of the primary tumour. These initial studies measured RE
Br. J. Cancer (1981) 43, 67 SOLUBLE AND NUCLEAR OESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER IN RELATION TO PROGNOSIS R. E. LEAKE*, L. LAING*, C. McARDLEt AND D. C. SMITH$ From the *Department of Biochemistry,
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationResection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationThis PDF is available for free download from a site hosted by Medknow Publications. (www.medknow.com).
Original Article Free full text available from www.cancerjournal.net Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy ABSTRACT
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationTHE temporal order in which patients with earlystage
THE NEW ENGLAND JOURNAL OF MEDICINE May, 199 THE SEQUENCING OF CHEMOTHERAPY AND RADIATION THERAPY AFTER CONSERVATIVE SURGERY FOR EARLY-STAGE BREAST CANCER ABRAM RECHT, M.D., STEVEN E. COME, M.D., I. CRAIG
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationWhat is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows:
February 3 rd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationOriginal Study. Abstract. Introduction. Clinical Breast Cancer February
Outcomes of Clinically Node-Negative Breast Cancer Without Axillary Dissection: Can Preserved Axilla Be Safely Treated With Radiation After a Positive Sentinel Node Biopsy? Naoko Sanuki, 1 Atsuya Takeda,
More informationRadiation Field Design and Patterns of Locoregional Recurrence Following Definitive Radiotherapy for Breast Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer Radiation Field Design and Patterns of Locoregional Recurrence Following Definitive
More informationGuidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017
Guidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017 Author: Dr Virginia Wolstenholme, Consultant Clinical Oncologist, Barts Health Date agreed: September 2017 Date to be
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationR. A. Nout Æ W. E. Fiets Æ H. Struikmans Æ F. R. Rosendaal Æ H. Putter Æ J. W. R. Nortier
Breast Cancer Res Treat (2008) 109:567 572 DOI 10.1007/s10549-007-9681-x EPIDEMIOLOGY The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated
More informationMinimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
Original article Annals of Oncology 15: 1633 1639, 2004 doi:10.1093/annonc/mdh434 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2012 September; 15(3): 329-336 Radiation Treatment in Pathologic N0-N1 Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery for Locally
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationOncologist. The. Controversies Regarding the Use of Radiation After Mastectomy in Breast Cancer
The Oncologist Controversies Regarding the Use of Radiation After Mastectomy in Breast Cancer THOMAS A. BUCHHOLZ, ERIC A. STROM, GEORGE H. PERKINS, MARSHA D. MCNEESE Department of Radiation Oncology, The
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationClinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
More informationCitation Hong Kong Practitioner, 1997, v. 19 n. 5, p
Title Management of primary breast cancer Author(s) Cheung, KL Citation Hong Kong Practitioner, 1997, v. 19 n. 5, p. 256-263 Issued Date 1997 URL http://hdl.handle.net/10722/146207 Rights This work is
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationClinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients
Original Article Radiat Oncol J 4;():-7 http://dx.doi.org/.857/roj.4... pissn 4-9 eissn 4-56 Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients Hee Ji
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More information